Podium & Poster Presentations at PepTalk 2015 Highlight the Ability of MaxCyte STX® and MaxCyte VLX® to Find More Relevant Candidates and Shorten the Antibody Development Timeline
Gaithersburg, MD, January 19, 2015 –MaxCyte®, Inc., the pioneer in scalable, high-performance cell transfection systems, will present data demonstrating titer and productivity improvements using flow transfection for transient gene expression and stable cell line generation in podium and poster presentations during CHI’s 14th Annual PepTalk: The Protein Science Week in San Diego, CA, January 19- 23, 2015. MaxCyte scientists will be available throughout the conference at Booth #318 to provide technical details on the operation and use of the MaxCyte STX® Scalable Transfection System and the MaxCyte VLX® Large Scale Transfection System in biotherapeutic discovery, development, and manufacturing. Dr. James Brady will present MaxCyte’s data in a podium presentation entitled, Protein Production with Flow Electroporation: Higher Titers, Cell Type Flexibility, and Scalability at 3:45 PM, Thursday, January 22, 2015.
“As the demand for protein therapeutics expands, future successes will depend on the ability to generate protein in the most relevant cell types for physiological activity and manufacturing and to enable process optimization through quick scale-up and scale-down,” says Doug Doerfler, President and CEO of MaxCyte. Inc. “From the earliest phases of discovery and development into biomanufacturing, companies using the MaxCyte transfection platform now have a powerful tool to generate antibodies and other recombinant proteins rapidly and reproducibly in their manufacturing cells in meaningful quantities for identification, characterization, and further development.”
MaxCyte will also present a scientific poster entitled Using Flow Electroporation to Find More Relevant Candidates and Shorten the Antibody Development Timeline, which will be available for viewing throughout the conference.
MaxCyte specializes in cell modification technologies to enable the discovery, development, manufacturing, and delivery of innovative therapeutic products. Drawing on its cell therapy expertise, MaxCyte designed a portfolio of products including the MaxCyte STX® Scalable Transfection System and MaxCyte VLX® Large Scale Transfection System, ideal tools for use in drug discovery research and screening and protein production environments. These products provide for the rapid development and consistent production of billions of (co)transfected primary cells, stem cells, and cell lines for protein and antibody production, for rapid response vaccine development, and for cell-based assays with comparable results and Seamless Scalability™ from the bench to HTS and pilot and production scale.
For more information visit /